Company intelligence / Profile preview

Vector BioPharma

Basel, Basel-Stadt, Switzerlandbiospace.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Vector BioPharma has developed a next-generation precision gene delivery platform that overcomes key limitations of traditional viral vectors—enabling large genetic cargoes (~36 kb), precise tissue/cell targeting, reduced immunogenicity, and tunable expression. The company has raised $30M Series A funding from Versant Ventures to advance its preclinical programs. No clinical results have been reported yet.

Therapeutic areas: OtherOncology
Modalities: Gene therapies (DNA-based therapeutics)Engineered adenoviral vectorsVirus-like particles for gene deliveryCell and gene therapy platforms
Industry: Biotech

Partnerships

Collaboration with iBET (Instituto de Biologia Experimental e Tecnológica) announced January 2023 to support development efforts.

Beyond the preview

Go deeper on Vector BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vector BioPharma.

Explore the full profile